Tag-Archive for ◊ Johnson and Johnson news ◊

• Thursday, January 23rd, 2014

Jan 21 (Reuters) – Healthcare company Johnson & Johnson cautioned Tuesday that prescription-drug sales would likely lose some momentum this year and forecast 2014 earnings at the lower end of Wall Street expectations, sending its shares down almost 2 percent. Chief Financial Officer Dominic Caruso cautioned that the growth rate of prescription drug sales will “decelerate” this […]

• Saturday, November 23rd, 2013

A New Jersey judge warned of several “rogue websites” by lawyers seeking to take advantage of Johnson & Johnson (JNJ)’s agreement to pay at least $2.47 billion to settle thousands of lawsuits over its recalled hip implants. Superior Court Judge Brian Martinotti heard a summary in Hackensack today of the settlement from lawyers who negotiated an […]

• Thursday, November 21st, 2013

A unit of Johnson & Johnson has agreed to pay an estimated $2.5 billion to settle thousands of lawsuits from individuals allegedly injured by the company’s artificial hip implants, the company announced Tuesday. The settlement, announced during a hearing in federal court in Ohio on Tuesday, would compensate an estimated 8,000 patients who underwent surgery […]

• Friday, November 15th, 2013

Johnson & Johnson officials reveal to MassDevice.com plans to restructure its diabetes division to “get in front” of pricing and reimbursement pressures, saying an unspecified number of layoffs will occur. Johnson & Johnson (NYSE:JNJ) told MassDevice.com today that it plans to make an unspecified number of job cuts, consolidate facilities and change the reporting structure on some of the sales […]

• Thursday, November 14th, 2013

Johnson & Johnson has tentatively agreed to a settlement that could reach up to $4 billion to resolve thousands of lawsuits filed by patients injured by a flawed all-metal replacement hip, said two lawyers briefed on the plan. The tentative plan, which must win court approval, represents one of the largest payouts for product liability […]

• Friday, November 08th, 2013

Johnson & Johnson will pay $2.2 billion to the U.S. government to end multiple investigations into kickbacks to pharmacists and the marketing of pharmaceuticals for off-label uses, a person familiar with the settlement said on Monday. The settlement with the company and its subsidiaries covers the marketing of schizophrenia treatment Risperdal and of heart drug […]

• Wednesday, October 16th, 2013

Johnson & Johnson has traditionally had a strong medical device and diagnostics sectors but the growth in both of those areas has slowed. In the second quarter of 2013, the device segment grew at a rate of 0.5%—ignoring the Synthes acquisition and currency fluctuations. The company is rumored to be mulling the sale of its […]

• Tuesday, October 15th, 2013

The year-old collaboration between DePuy Synthes Spine and Brainlab now includes co-marketing a new product, in addition to continued development on surgical navigation and imaging devices. Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes Spine said it’s expanding its collaboration with Brainlab on surgical navigation and imaging devices, in addition to co-marketing Brainlab’s Airo Mobile Intraoperative […]

• Friday, September 27th, 2013

During the last decade, more than 1,500 Americans died after accidentally taking too much of a drug renowned for its safety: acetaminophen, one of the nation’s most popular pain relievers. Acetaminophen – the active ingredient in Tylenol – is considered safe when taken at recommended doses. Tens of millions of people use it weekly with […]

• Friday, September 06th, 2013

The U.S. Dept. of Defense grants Philips 2 contracts worth a potential $63.3 million and Johnson & Johnson lands a federal defense deal worth $9.6 million. The U.S. Defense Dept. handed out 3 new healthcare contracts to Philips Healthcare (NYSE:PHG) and Johnson & Johnson (NYSE:JNJ), totaling a potential worth of nearly $73 million for medical equipment. In a contract […]